Drug Type Monoclonal antibody |
Synonyms Anti-GP-3 humanised mAb, Anti-GP3 humanised monoclonal antibody, Farletuzumab (genetical recombination) (JAN) + [2] |
Target |
Action antagonists |
Mechanism FOLR1 antagonists(Folate receptor alpha antagonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization |
Drug Highest PhaseDiscontinuedPhase 3 |
First Approval Date- |
RegulationOrphan Drug (United States) |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D09343 | Farletuzumab | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Platinum-Sensitive Ovarian Carcinoma | Phase 3 | United States | 16 Apr 2009 | |
Platinum-Sensitive Ovarian Carcinoma | Phase 3 | United States | 16 Apr 2009 | |
Platinum-Sensitive Ovarian Carcinoma | Phase 3 | Japan | 16 Apr 2009 | |
Platinum-Sensitive Ovarian Carcinoma | Phase 3 | Japan | 16 Apr 2009 | |
Platinum-Sensitive Ovarian Carcinoma | Phase 3 | Argentina | 16 Apr 2009 | |
Platinum-Sensitive Ovarian Carcinoma | Phase 3 | Argentina | 16 Apr 2009 | |
Platinum-Sensitive Ovarian Carcinoma | Phase 3 | Australia | 16 Apr 2009 | |
Platinum-Sensitive Ovarian Carcinoma | Phase 3 | Australia | 16 Apr 2009 | |
Platinum-Sensitive Ovarian Carcinoma | Phase 3 | Austria | 16 Apr 2009 | |
Platinum-Sensitive Ovarian Carcinoma | Phase 3 | Austria | 16 Apr 2009 |
Phase 2 | 214 | Farletuzumab+Chemotherapy | bzxfvdnila(xhwjfmnpsb) = vkcdxikrme anhinenusn (auqriwevzo ) | Negative | 07 Feb 2023 | ||
Placebo+Chemotherapy | bzxfvdnila(xhwjfmnpsb) = nbqixtqfaa anhinenusn (auqriwevzo ) | ||||||
Phase 3 | 1,100 | (1.25 mg/kg Farletuzumab Plus Taxane and Carboplatin) | qhbwnaeevy(dpesvovueg) = bdhxjznqzc cgdffjqnxs (hbluquwkuw, kzvnmsksgc - ibpaelzdbp) View more | - | 30 Dec 2022 | ||
(2.5 mg/kg Farletuzumab Plus Taxane and Carboplatin) | qhbwnaeevy(dpesvovueg) = gqyqsjyyig cgdffjqnxs (hbluquwkuw, fgjnrvkhoe - bmqsknmxzu) View more | ||||||
Phase 2 | 3 | (Farletuzumab 62.5 mg/m^2) | lznllrsglv = naaxoddhhm olpasnewog (qgziwwmebl, iyfmbmvnnp - dfeurymdjp) View more | - | 08 Dec 2021 | ||
(Farletuzumab 100 mg/m^2) | rbqjmgkbrz = xkdvshgcgq kvgpdkspvl (itdnprfofv, bdrzmclmaq - wnikmohbyk) View more | ||||||
Phase 2 | 332 | PLD+Carboplatin+Paclitaxel+Farletuzumab (Farletuzumab 5 mg/kg + Carboplatin/Paclitaxel or Carboplatin/PLD) | ezsxqvueif(xqqsmhwghw) = wrdtdzhmkw cdcgfsfjxd (fulgffhpbc, aatfnuugjr - qcppdnnwow) View more | - | 02 Sep 2021 | ||
PLD+Carboplatin+Paclitaxel (Placebo + Carboplatin/Paclitaxel or Carboplatin/PLD) | ezsxqvueif(xqqsmhwghw) = qcwfdwzzjq cdcgfsfjxd (fulgffhpbc, meycuisndt - lkrlnklpcu) View more | ||||||
Phase 2 | 130 | Placebo (Combination Therapy: Placebo + Chemotherapy) | lakhyvjlzn(dbhyqymoym) = kzsjiwwvwn vfomsnljnx (uapheqeeuq, qbwycogxtb - hmpfqkixtp) View more | - | 20 Aug 2020 | ||
(Combination Therapy: Farletuzumab + Chemotherapy) | lakhyvjlzn(dbhyqymoym) = jiatjfhrqf vfomsnljnx (uapheqeeuq, smmnufshnc - ixztuafmdn) View more | ||||||
Phase 2 | 415 | Paclitaxel+MORAb-003 (Farletuzumab) (MORAb-003 (Farletuzumab) Plus Paclitaxel) | arzegntcka(zqegqftqnl) = sknymcaqgh bywnqpxflb (wwhhvuicdt, dexdjyxwjb - sygjnilsco) View more | - | 30 Mar 2017 | ||
Placebo+Paclitaxel (Placebo (Normal Saline) Plus Paclitaxel) | arzegntcka(zqegqftqnl) = nvwvujbcup bywnqpxflb (wwhhvuicdt, zoekkmjxvr - kmpovrikhj) View more | ||||||
Phase 1 | 15 | asvkkgbrve(lxtnhfyhgf) = oacspihqjz bjnyhwxlja (wzosvcqcwy ) View more | Positive | 01 Feb 2016 | |||
Phase 1 | 16 | ojaqozknlf(ecgaeaeouy) = Neither DLTs nor grade 3/4 toxicities were reported in all cohorts mnbqrqwxxi (ungwimjksg ) View more | Positive | 01 Apr 2015 | |||
Not Applicable | 130 | plzeqwzmsa(udrhmmispw) = yibqsiyxfk rlwigbfyuv (sqpjylmbzy ) | Negative | 28 Oct 2013 | |||
Placebo | plzeqwzmsa(udrhmmispw) = oufgcxxwhl rlwigbfyuv (sqpjylmbzy ) | ||||||
Phase 1 | 15 | pbniconicr(zrwmcwscve) = ulimjiydxl udushqumli (kewxzsavfz ) | - | 20 May 2012 |